Ameriprise
KTTA icon

Ameriprise’s Pasithea Therapeutics KTTA Stock Holding History

Ameriprise’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1M Sell
1,350,896
-579,232
-30% -$484K ﹤0.01% 3296
2025
Q4 		$2.49M Buy
+1,930,128
New +$1.7M ﹤0.01% 2876

Other funds holding KTTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameriprise's KTTA Position: Q1 2026 in Review

Ameriprise reduced its Pasithea Therapeutics (KTTA) stake by 30% in Q1 2026, selling an estimated $484K and leaving 1,350,896 shares worth $1M. The position accounts for ﹤0.01% of the portfolio, ranked #3296.

Ameriprise first reported a position in KTTA in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.49M in Q4 2025. 21 funds tracked by Wall St. Rank hold KTTA as of Q1 2026.

  • Ameriprise held 1,350,896 shares of Pasithea Therapeutics worth $1M as of Q1 2026.
  • Ameriprise sold 579,232 Pasithea Therapeutics shares in Q1 2026, an estimated $484K.
  • Pasithea Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3296 holding.
  • Ameriprise first reported a position in Pasithea Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Ameriprise's Pasithea Therapeutics position peaked at $2.49M in Q4 2025.
  • 21 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.